Article

Cutera acquires IRIDEX aesthetic unit

Cutera Inc. and IRIDEX Corp. have entered into a binding agreement for Cutera to purchase certain assets of IRIDEX’s global aesthetic business for about $5.1 million.

Brisbane and Mountain View, CA-Cutera Inc. and IRIDEX Corp. have entered into a binding agreement for Cutera to purchase certain assets of IRIDEX’s global aesthetic business for about $5.1 million.

Currently, both companies serve the growing global aesthetic market, with IRIDEX’s strength in vascular treatments, a mainstay in the dermatology specialty. This proposed strategic combination is expected to advance Cutera’s presence among physicians and create a stronghold in the vascular aesthetic sector.

Kevin Connors, president and chief executive officer of Cutera, said the deal will create one of the most comprehensive portfolios of vascular laser solutions in the industry.

Dominik Beck, PhD, president and chief executive officer of IRIDEX, said the deal allows his company to refocus its resources on “the substantial and growing ophthalmology opportunity that is core to IRIDEX’s future.”

The transaction is expected to close in early 2012.

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.